Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...
Optimizing Humira coverage is not just about reducing costs—it's about delivering effective, compassionate care while ...
Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to ...
The obesity medicine field has gained a new entrant, with AbbVie licensing an experimental drug from a Danish company.
Pharmacy benefits manager (PBM) RxPreferred has announced plans to offer the Humira biosimilar Yusimry through Mark Cuban Cost Plus Drugs – an online pharmacy launched by celebrity investor and ...
AbbVie's strategic move into the obesity market through a partnership with Gubra A/S shows potential but won't impact revenue ...
GlobalData on MSN11d
Biosimilars drive Sandoz growth ahead of unclear tariff effects in 2025Looking ahead to 2025, Sandoz said it expects net sales to grow by a mid-single digit percentage in constant currencies.
or commonly used biological drugs like Humira, prescribed for rheumatoid arthritis. A 2024 study from Beth Israel Deaconess Medical Center found that about 15 million Americans use the new ...
SmithRx, a transparent, 100% pass-through modern pharmacy benefits manager (PBM), today announced a major expansion to its Connect 360 Autoimmune Prog ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback